Deconstructing the Alternative Lengthening of Telomeres: Integromics Prioritizes Five Master Hubs Dictating Clinical Survival and Therapeutic Vulnerabilities

Abstract

Simple Summary Certain aggressive cancers, such as sarcomas and brain gliomas, achieve cellular “immortality” by lengthening their telomeres using a survival mechanism called ALT. Currently, researchers look for specific DNA mutations to detect ALT, but this method is often insufficient for accurately predicting patient outcomes. In this study, we developed a new diagnostic signature based on the activity of 28 specific genes. We demonstrated this tool provides improved prognostic discrimination of tumor aggressiveness and patient survival than traditional mutation tests. Furthermore, we mapped how these genes interact, discovering they consume high amounts of cellular energy and DNA building blocks to keep the cancer alive. By understanding this machinery, we identified existing FDA-approved drugs, specifically PARP inhibitors and antimetabolites, that are predicted to inhibit this cancer survival engine through potential metabolic starvation and DNA damage. This research offers a robust prognostic framework to stratify high-risk tumors and provides an in silico hypothesis-generating framework.